EVGNHealthcare · BiotechnologyThe 1 Wall Street analysts covering Evogene Ltd. hold a median 12-month price target of $2.15 — +284.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Evogene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EVGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +284.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 May 2025 | Lake Street | Maintains | Buy | — |
| 22 May 2025 | Lake Street | Maintains | Buy | $5.00 → $3.50 |
| 23 Aug 2024 | Lake Street | Maintains | Buy | — |
| 2 Oct 2023 | Alliance Global Partners | Initiates | Buy | — |
| 18 Aug 2023 | Lake Street | Maintains | Buy | — |
| 21 July 2023 | Roth MKM | Maintains | Buy | — |
| 2 May 2023 | Lake Street | Initiates | Buy | — |
| 12 Sept 2022 | Aegis Capital | Maintains | Buy | — |
| 2 Sept 2022 | Roth MKM | Maintains | Buy | — |
| 8 Oct 2021 | Roth Capital | Initiates | Buy | — |
| 29 July 2021 | Aegis Capital | Initiates | Buy | — |
| 1 Dec 2020 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 Nov 2014 | Credit Suisse | Maintains | Outperform | $24 → $22 |
| 17 Dec 2013 | Deutsche Bank | Initiates | Buy | — |
| 16 Dec 2013 | Credit Suisse | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVGN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 26% of US stocks
Cheaper than 82% of US stocks
Cheaper than 63% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 74% of US stocks
Higher than 6% of US stocks
Higher than 23% of US stocks
Higher than 8% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Evogene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Evogene Ltd.'s Q2 2026 earnings call, covering management's discussion of the company's quarterly financial results and business developments.
Why it matters — EVGN watchers would find this transcript a primary source of detail on the company's Q2 2026 performance and strategic outlook.
Evogene reported its second-quarter and first-half 2026 financial results, showing a reduced net loss of approximately $1.8 million for Q2 2026 versus $4.7 million in Q2 2025, and projected 2026 cash burn of $8.5–$9.5 million, down from $14.4 million in 2025. The company continued its strategic transformation into an AI-driven computational chemistry firm, with six active drug development collaborations and an expanded virtual chemical space of about 110 billion molecules.
Why it matters — EVGN watchers would care because the results show reduced losses and lower projected cash burn alongside progress in its AI-driven drug development collaborations and computational chemistry platform.
Evogene announced that Chairman Nir Nimrodi will join the company's quarterly results conference call on August 18, 2026, at 9:00 AM ET, to address the current situation regarding dissident shareholders. The call, announced via PRNewswire on August 14, 2026, will be conducted via Zoom.
Why it matters — EVGN watchers will be interested because the chairman's planned remarks directly address the ongoing situation with dissident shareholders, providing clarity on a governance matter that could affect the company's direction.
Evogene Ltd. announced it will release its second quarter 2026 financial results on August 18, 2026, with a Zoom conference call scheduled for 9:00 AM ET that same day.
Why it matters — Investors and analysts monitoring Evogene will gain insight into the company's recent financial performance and operational progress during the earnings call.
The 1 Wall Street analysts covering Evogene Ltd. have a median 12-month price target of $2.15, with estimates ranging from $2.15 to $2.15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Evogene Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evogene Ltd. 35 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Evogene Ltd. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +284.0% from the last close, and Ticker Nerd's factor model ranks Evogene Ltd. 35 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Evogene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.15 to $2.15 over the next 12 months.
Evogene Ltd. returned -55.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Evogene Ltd. is a biotechnology company that focuses on developing innovative solutions across various life science-based industries, including agriculture, pharmaceuticals, and industrial applications.
The most recent item we track (Seeking Alpha, 18 Aug 2026): "Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Evogene Ltd.'s Q2 2026 earnings call, covering management's discussion of the company's quarterly financial results and business developments.
Evogene Ltd. is a biotechnology company that focuses on developing innovative solutions across various life science-based industries, including agriculture, pharmaceuticals, and industrial applications. By leveraging its unique computational predictive biology platform, Evogene aims to evolve new products through enhanced efficiency and precision. The platform integrates extensive databases, advanced algorithms, and big data analytics to identify and optimize traits that increase yield, resistance, and sustainability in crops or address critical health and industrial challenges. As a key player in sectors such as agrochemicals, seed development, and biotechnology, Evogene has established collaborations with leading companies to commercially scale its proprietary discoveries. The company is headquartered in Rehovot, Israel, contributing significantly to advancements in biotechnology that enhance productivity and sustainability, reflecting its growing importance in the global market for biologically driven solutions.
CEO Mr. Ofer Haviv CPA · 52 employees · Israel · https://www.evogene.com